SecBot SecBot
8-K ·Filed Feb 26, 2026

TRDA

Entrada Therapeutics, Inc.
BEARISH
Impact 6/10
Horizonmonths Processed8mo ago SEC0001689375-26-000009
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The sharp decline in collaboration revenue and resulting net loss are significant negative developments, despite positive clinical updates. Traders should monitor upcoming clinical data readouts in 2026 as key catalysts, but the financial deterioration suggests increased risk. The cash runway into Q3 2027 provides near-term stability, but future dilution risk may increase if revenue does not recover.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$12.79
T+0 close · Feb 26, 2026 · via day close
Latest settled
−50.66%
T+60 · $6.31
Vs SPY
−58.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $12.79entry
  2. T+1 · 9mo ago −6.72%α −6.27% · $11.93
  3. T+5 · 9mo ago −9.15%α −8.02% · $11.62
  4. T+20 · 8mo ago −3.75%α +2.65% · $12.31
  5. T+60 · 6mo ago −50.66%α −58.42% · $6.31
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Entrada Therapeutics reported financial results for Q4 and full year 2025, showing a significant decline in collaboration revenue and a shift from net income to a net loss compared to the prior year. The company highlighted clinical progress in its DMD and DM1 programs, including a positive DMC recommendation to advance the ELEVATE-44-201 study to a higher dose cohort. Cash runway is expected into Q3 2027 with $295.7 million in cash and marketable securities.

Key Financial Metrics

Revenue
$25.4M
-88.0% YoY
EPS
$-3.47

Key Facts

  • Collaboration revenue dropped to $25.4 million in 2025 from $210.8 million in 2024, primarily due to the substantial completion of VX-670 collaboration research activities in Q1 2025.
  • Net loss was $143.8 million for 2025 compared to net income of $65.6 million in 2024.
  • Cash, cash equivalents, and marketable securities were $295.7 million as of December 31, 2025, down from $420.0 million as of December 31, 2024.
  • The Independent Data Monitoring Committee recommended initiating Cohort 2 at a higher dose (12 mg/kg) in the ELEVATE-44-201 study without protocol modifications.
  • The company expects to report data from ELEVATE-44-201 Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026.

Financial Impact

Revenue declined by $185.4 million YoY, resulting in a net loss of $143.8 million in 2025 versus net income of $65.6 million in 2024.

revenuenet incomecash

Risk Factors

  • Significant decline in collaboration revenue with no indication of new major partnerships to replace VX-670 funding.
  • Increased R&D and GA expenses are outpacing any new revenue streams, leading to substantial cash burn.
  • Clinical trial timelines and outcomes remain uncertain, with no guarantee of regulatory approval even with positive data readouts.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001689375-26-000009
Document: trda-20260226.htm0001689375-26-000009
Document: 0001689375-26-000009-index-headers.html0001689375-26-000009
Document: 0001689375-26-000009-index.html0001689375-26-000009
Document: 0001689375-26-000009.txt0001689375-26-000009

US Market Status

Market Closed · Opens in 6h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026